Caribou Biosciences (CRBU) Accounts Payables (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Accounts Payables of $3.5 million for Q1 2026, down 9.55% year-over-year from $3.9 million in Q1 2025, and down 39.43% quarter-over-quarter from $5.8 million in Q4 2025.
Caribou Biosciences (CRBU) Accounts Payables (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Accounts Payables for 7 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 9.55% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $3.5 million (down 9.55% YoY), while the FY2025 annual figure was $5.8 million, up 133.56% from the prior year.
- Accounts Payables slipped to $3.5 million in Q1 2026 per CRBU's latest filing, from $5.8 million in the prior quarter.
- Across five years, Accounts Payables topped out at $5.9 million in Q1 2024 and bottomed at $426000.0 in Q2 2022.
- Historically, Accounts Payables has averaged $3.0 million across 5 years, with a median of $3.1 million in 2023.
- Annual changes were most pronounced in 2022 — Accounts Payables slumped 89.43% — and 2023, when it soared 940.61%.
- Caribou Biosciences' Accounts Payables stood at $1.1 million in 2022, then surged by 172.25% to $3.1 million in 2023, then declined by 20.64% to $2.5 million in 2024, then jumped by 133.56% to $5.8 million in 2025, then slumped by 39.43% to $3.5 million in 2026.
- Business Quant data shows CRBU's Accounts Payables at $3.5 million in Q1 2026, $5.8 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | 3.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.08 Mn |
| Mar 31, 2026 | 3.50 Mn |
| Dec 31, 2025 | 5.78 Mn |
| Sep 30, 2025 | 3.80 Mn |
| Jun 30, 2025 | 3.24 Mn |
| Mar 31, 2025 | 3.87 Mn |
| Dec 31, 2024 | 2.48 Mn |
| Sep 30, 2024 | 2.70 Mn |
| Jun 30, 2024 | 3.23 Mn |
| Mar 31, 2024 | 5.94 Mn |
| Dec 31, 2023 | 3.12 Mn |
| Sep 30, 2023 | 2.38 Mn |
| Jun 30, 2023 | 4.43 Mn |
| Mar 31, 2023 | 2.65 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Sep 30, 2022 | 1.23 Mn |
| Jun 30, 2022 | 426,000.00 |
| Mar 31, 2022 | 1.81 Mn |
| Dec 31, 2021 | 3.99 Mn |
| Sep 30, 2021 | 3.48 Mn |